VKTX Stock Recent News

VKTX LATEST HEADLINES

VKTX Stock News Image - fool.com

Viking Therapeutics has the potential to be a great growth stock. The company, however, faces a lot of competition in the GLP-1 drug market.

fool.com 2024 Jun 15
VKTX Stock News Image - zacks.com

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $52.10, denoting a -0.69% change from the preceding trading day.

zacks.com 2024 Jun 13
VKTX Stock News Image - zacks.com

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

zacks.com 2024 Jun 13
VKTX Stock News Image - fool.com

Viking Therapeutics just reported (more) positive phase 2 clinical trial results. Though the company's shares dropped, interested investors shouldn't worry.

fool.com 2024 Jun 09
VKTX Stock News Image - zacks.com

Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $55.99, signifying a +1.78% move from its prior day's close.

zacks.com 2024 Jun 07
VKTX Stock News Image - fool.com

Viking Therapeutics stock took a hit this week in response to a clinical update for its midstage liver disease drug. This pullback seems unwarranted, given the company's pivot to weight loss.

fool.com 2024 Jun 06
VKTX Stock News Image - zacks.com

Viking Therapeutics (VKTX) reports promising 52-week treatment data from a mid-stage study on its experimental NASH drug. However, shares drop as management did not provide any info on future plans.

zacks.com 2024 Jun 05
VKTX Stock News Image - prnewswire.com

Up to 75% of Patients Treated with VK2809 Achieved NASH Resolution with No Worsening of Fibrosis as Compared to 29% for Placebo (p=0.0001) Up to 57% of VK2809-Treated Patients Achieved ≥1-Stage Improvement in Fibrosis with No Worsening of NASH as Compared to 34% for Placebo (p

prnewswire.com 2024 Jun 04
VKTX Stock News Image - fool.com

Biotechs that aspire to be disruptive are quite risky. However, they do offer the chance of disproportionate rewards.

fool.com 2024 Jun 03
VKTX Stock News Image - zacks.com

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $62.26, representing a +0.78% change from its previous close.

zacks.com 2024 May 31
10 of 50